You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
SBIR TOPIC 97- PHASE II- MINIMALLY INVASIVE TEST FOR CHEMOTHERAPY-INDUCED CARDIOTOXICITY
SBC: ACCEL DIAGNOSTICS, LLC Topic: NHLBICardiovascular toxicityCVTxis a serious short and long term complication of many anti cancer chemotherapeutic regimensZamoranoLancellotti et alIn this PhaseSBIR submission to continue the development and validation of Accel Diagnosticsminimally invasiverapidcost effective and connected blood testthe pScreen CVTx TMfor the early detection and continuous of chemotheropy induced CVTx
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Advanced development of a novel nanoparticle conjugate vaccine for Salmonella Paratyphi A
SBC: KJ BIOSCIENCES LLC Topic: NIAIDSalmonella Paratyphi ASParatyphi Ais a major cause of life threatening enteric feverThere is no vaccine available against this pathogenIn the SBIR phase I studieswe have successfully demonstrated the technical feasibility of a novel nanoparticle conjugate vaccine candidate for SParatyphi AIt is based on O polysaccharideOPSantigen conjugated to a novel and highly advantageous nanoparticle protein c ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
TOPIC #366- PHASE II SBIR CONTRACT- CLONOGENIC HIGH- THROUGHPUT ASSAY FOR SCREENING RADIATION MODULATION
SBC: SUVICA INC Topic: NCIClonogenic assays measure the ability of single cells to proliferate and form a colonyThis process approximates closely the regrowth and recurrence of tumors after treatment with radiation or chemotherapyproviding an assay to screen for drugs that block this processYetclonogenic assays are labor intensive and too cumbersome for high throughout screeningHTSof compound librariesHere we propose to de ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Improving Spatiotemporal Precision in Noninvasive Electrical Neuromodulation
SBC: Brain Electrophysiology Laboratory Company, LLC Topic: 101This application describes the commercialization of the Geodesic Transcranial Electrical Neuromodulation (GTEN) technology to achieve noninvasive neuromodulation with improved spatiotemporal precision. The GTEN system enables both EEG source analysis and configurable electrical neuromodulation with the 256 electrodes of the Geodesic Sensor Net. Now in beta release to selected research customers, t ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Preformulation and formulation development of Fenrock, an Abuse-resistant Fentanyl Transdermal Patch
SBC: PAIN THERAPEUTICS, INC. Topic: NIDAProject Summary Abstract Under this Fast Track proposalwe will develop Fenrockan abuse deterrent transdermal fentanyl patch based on our proprietary co crystal of naltrexoneNTXand its carefully selected conformermethyl furfuralMFFThis NTXMFFco crystalNTX Cohas the desired properties to stay in a crystalline solid form in the patch when applied to skin as intended but to dissociate to deliver NTX w ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Whole-organ bioreactor with integrated nondestructive 3D molecular imaging
SBC: Sonovol, Inc. Topic: NHLBIAbstract Significance: Donor tissue shortage remains a critical problem in lung transplantation. Recent advances in tissue engineering have allowed for the possibility of generating bioengineered lungs from decellularized organ scaffolds. These scaffolds, created from the donor’s tissue, become functionalized after recellularization with a patient’s own cells. However, translation of whole-lun ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Personal Mercury Monitor for Exposure Measurements
SBC: LUDLUM MEASUREMENTS INC Topic: 113Personal Mercury Monitor for Exposure Measurements Project Summary/AbstractWorkers in the oil and natural gas industry are vulnerable to exposure to toxic mercury (Hg) vapor as a result of routine inspection and maintenance of equipment such as compressors and other process equipment that concentrate species of low volatility over time. Exposure of workers to elemental mercury vapor is of concern ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of a Neonatal Abstinence Syndrome Therapy
SBC: Mu Therapeutics Inc. Topic: NIDANeonatal Abstinence Syndrome (NAS) has skyrocketed in recent years as a result of the opioid epidemic plaguing this country. Since 2000, the number of babies affected by NAS has increased nearly 5-fold. Every 25 minutes a baby is born suffering from opioid withdrawal, often prematurely with developmental problems and potential long-term adverse effects including cognitive impairment. Approximately ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
High Throughput CRISPR/Cas9 cell line generation using the CellRaft Array
SBC: CELL MICROSYSTEMS INC Topic: 400Project SummaryGenome editing technologies, such as CRISPR/Cas9 provide a rapid, and targeted means of both knocking out gene expression and knocking in gene modifications. Since our initial Phase I submission, the utility of CRISPR technology has expanded beyond the generation of cell lines, to forward genetic screening, in vivo manipulation of gene expression and even human therapeutics. Phase I ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Point-of-Care Prognostic Tool for Sepsis
SBC: MBIO DIAGNOSTICS INC Topic: 300Sepsis is a devastating cause of morbidity and mortality in intensive care units (ICUs), with estimates of U.S. incidence ranging from 894,000 to 3.1 million cases annually. The heterogeneity of clinical presentation (etiology, patient history, severity, etc.) creates a major challenge for patient management and has significantly complicated development of new therapies, almost all of which have f ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health